Caris Life Sciences (CAI) Assets Average (2025 - 2026)

Caris Life Sciences (CAI) recorded quarterly Assets Average of $1.1 billion in Q1 2026, up 8.43% quarter-over-quarter from $1.1 billion in Q4 2025.

Caris Life Sciences (CAI) Assets Average (2025 - 2026) Analysis & Trends

Caris Life Sciences' Assets Average history runs 2 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

In Q1 2026, Assets Average changed N/A year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (changed N/A YoY), while the FY2025 annual figure was $734.7 million, changed N/A from the prior year.
Assets Average was $1.1 billion for Q1 2026 at Caris Life Sciences, up from $1.1 billion in the prior quarter.
In the past five years, Assets Average ranged from a high of $1.1 billion in Q1 2026 to a low of $969.8 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Assets Avg. (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	33.42 Mn
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	795.91 Mn
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	13.04 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	1.72 Bn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	26.03 Mn
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	40.89 Mn
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	10.06 Mn
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	26.06 Bn
9	Abivax	91.96 Bn	91.96 Bn	-	660.38 Mn
10	Caris Life Sciences	5.22 Bn	4.40 Bn	171.13 Mn	1.14 Bn

Download Data